Gabapentin

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transient Insomnia

Conditions

Transient Insomnia

Trial Timeline

Aug 1, 2006 โ†’ Jan 1, 2007

About Gabapentin

Gabapentin is a phase 3 stage product being developed by Pfizer for Transient Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00659100. Target conditions include Transient Insomnia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (10)

NCT IDPhaseStatus
NCT01441401Pre-clinicalCompleted
NCT00620555Phase 3Completed
NCT00603473Phase 3Completed
NCT00567268Pre-clinicalCompleted
NCT00659100Phase 3Completed
NCT00577967Pre-clinicalUNKNOWN
NCT00533455Phase 3Terminated
NCT00137735Phase 3Completed
NCT00644748ApprovedCompleted
NCT00169013ApprovedCompleted

Competing Products

10 competing products in Transient Insomnia

See all competitors
ProductCompanyStageHype Score
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - TabletsEli LillyPhase 1
33
Gabapentin + Gabapentin + PlaceboPfizerPhase 3
76
Gabapentin + Gabapentin + PlaceboPfizerPhase 3
76
Gabapentin + Gabapentin + PlaceboPfizerPhase 3
76
Gabapentin + PlaceboPfizerPhase 3
76
Gabapentin + Gabapentin + PlaceboPfizerPhase 3
76
Gabapentin + PlaceboPfizerPhase 3
76
Milvexian + PlaceboBristol Myers SquibbPhase 3
76
Apixaban + WarfarinBristol Myers SquibbPhase 3
76
Levosimendan + PlaceboOrion CorporationPhase 2
49